Condition: Hidradenitis Suppurativa · Sponsor: UCB Biopharma SRL
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
This description comes directly from the study's public registry record.
UCB Cares · +18445992273 · ucbcares@ucb.com
UCB Cares · 001 844 599 2273
Always discuss trial participation with your own doctor first.
| Hs0006 50175 | Phoenix, Arizona, United States | Recruiting |
| Hs0006 50708 | Roseville, California, United States | Recruiting |
| Hs0006 50684 | Sacramento, California, United States | Active Not Recruiting |
| Hs0006 50707 | Washington D.C., District of Columbia, United States | Recruiting |
| Hs0006 50199 | Miami, Florida, United States | Recruiting |
| Hs0006 50712 | Bowling Green, Kentucky, United States | Recruiting |
| Hs0006 50178 | Clarkston, Michigan, United States | Recruiting |
| Hs0006 50710 | Fort Gratiot, Michigan, United States | Recruiting |
| Hs0006 50711 | Troy, Michigan, United States | Recruiting |
| Hs0006 50706 | Chapel Hill, North Carolina, United States | Recruiting |
| Hs0006 50202 | Fairborn, Ohio, United States | Recruiting |
| Hs0006 50201 | Arlington, Texas, United States | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06921850